DCGI Approves ENTOD Pharmaceuticals' PresVu Eye Drops, Enabling Spectacle-Free Reading For Presbyopia Patients
Entod Pharmaceuticals Limited is recognized as one of the leading players in the Indian Pharmaceuticals industry, recently granted Final Approval by the Drug Controller General of India for its Novel Presbyopia medicine pres뷰 eye drops, marking a quantum leap in the management of presbyopia. This recommendation at CDSCO follows the approval by the SEC, considering the potential of the product to reduce the dependence on reading glasses in people affected with this common age-related vision condition. PresVu is an innovative product; it is the first eye drop in India, meant for dealing with presbyopia, which normally affects people above 40 years of age. The formulation and process of PresVu are also pending patent approval, flagging the innovativeness.
Besides improving near vision, PresVu has the additional advantage of lubricating the eyes, thus adding comfort to the user. These eye drops make use of an advanced dynamic buffer technology that quickly adjusts to tear pH levels to ensure continued safety and efficacy for extended use, meeting the need for a long-term solution. Presbyopia is the natural result of aging, ranging from 1.09 billion to 1.80 billion people around the world, thereby affecting domestic productivity and the quality of life.
With this condition, one has some problem in focusing on close objects; individuals with presbyopia often hold reading materials at arm's length to clearly see them. Diagnosis is confirmed by a simple eye exam. That presbyopia is widespread makes accessible treatments like PresVu all the more important to increase the capability of an individual to perform activities. Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, said, "This DCGI approval represents a major step forward in our mission to revolutionize eye care in India. PresVu is not just a product; it's a solution that offers greater visual independence to millions, reflecting our commitment to innovation and affordable healthcare solutions."
The clinical benefits of PresVu were emphasized by leading experts in ophthalmology, Dr. Dhananjay Bakhle and Dr. Aditya Sethi. Dr. Bakhle pointed out its rapid efficacy and a very favorable safety profile; Dr. Sethi pointed out its potential to change patients' quality of life by enhancing near vision within 15 minutes and offering a non-invasive alternative to reading glasses, contact lenses, and surgical interventions.
As ENTOD Pharmaceuticals continues to innovate and align with the 'Make in India' initiative, the forthcoming commercial launch of PresVu strengthens its commitment to increase access to health and improvement in outcomes throughout India.
